AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
AstraZeneca‘s stock jumped as much as 4% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former smokers and in the overall […]
Health
